SCHEMBL1264589

SCHEMBL1264589

CCc1cc(OC)cc(=O)o1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.45
HPGD P15428 7/20 0.45
HSD17B10 Q99714 6/20 0.45
TP53 P04637 2/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
MAPT P10636 2/20 0.45
CASP1 P29466 1/20 0.45
CASP7 P55210 1/20 0.45
CYP3A4 P08684 2/20 0.42
KDM4E B2RXH2 5/20 0.41
TDP1 Q9NUW8 2/20 0.41
LMNA P02545 1/20 0.41
GAA P10253 1/20 0.41
SLC22A12 Q96S37 3/20 0.40
CYP2D6 P10635 2/20 0.40
L3MBTL1 Q9Y468 2/20 0.39
GLA P06280 1/20 0.39
DYRK1A Q13627 1/20 0.38
CA12 O43570 1/20 0.38
CA1 P00915 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22149734 0.82 ALDH1A1 (0.44) ALDH1A1HPGDHSD17B10TP53SMN1; SMN2
SCHEMBL5363155 0.82 ALDH1A1 (0.47) ALDH1A1HPGDHSD17B10TP53SMN1; SMN2
SCHEMBL10660422 0.79 CA9 (0.47) ALDH1A1HPGDHSD17B10MAPTKDM4E
SCHEMBL10337891 0.79 MAPT (0.53) ALDH1A1SMN1; SMN2MAPTTDP1L3MBTL1
SCHEMBL10337853 0.79 MAPT (0.53) ALDH1A1SMN1; SMN2MAPTTDP1L3MBTL1
SCHEMBL9901344 0.75 PLA2G2A (0.47) TP53TDP1CA12CA1CA3
SCHEMBL9016228 0.75 PPARG (0.50) ALDH1A1HPGDHSD17B10TP53SMN1; SMN2
Dihydro-5,6-Dehydrokawain SCHEMBL19679894 0.74 PPARG (0.59) ALDH1A1HPGDTP53SMN1; SMN2MAPT
SCHEMBL1263805 0.72 CA1 (0.54) ALDH1A1HPGDHSD17B10TP53SMN1; SMN2
SCHEMBL11854129 0.72 MAPT (0.64) ALDH1A1HPGDHSD17B10SMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2066662-B1 SERINE HYDROLASE INHIBITORS KYORIN SEIYAKU KK (JP) 2012-12-05 EP disclosed
EP-2066662-B1 SERINE HYDROLASE INHIBITORS KYORIN SEIYAKU KK (JP) 2012-12-05 EP disclosed
US-7879846-B2 e.g. 2-(2-Imidazol-1-yl-pyridin-3-yl)-5-methyl-4H-benz[d][1,3]oxazin-4-one ; neutrophil elastase inhibitor; antiinflammatory agent, respiratory system disorders Kyorin Pharmaceutical Co.., Ltd. (JP) 2011-02-01 US disclosed
US-7879846-B2 e.g. 2-(2-Imidazol-1-yl-pyridin-3-yl)-5-methyl-4H-benz[d][1,3]oxazin-4-one ; neutrophil elastase inhibitor; antiinflammatory agent, respiratory system disorders Kyorin Pharmaceutical Co.., Ltd. (JP) 2011-02-01 US disclosed
US-7879846-B2 e.g. 2-(2-Imidazol-1-yl-pyridin-3-yl)-5-methyl-4H-benz[d][1,3]oxazin-4-one ; neutrophil elastase inhibitor; antiinflammatory agent, respiratory system disorders Kyorin Pharmaceutical Co.., Ltd. (JP) 2011-02-01 US disclosed
EP-2066662-A2 SERINE HYDROLASE INHIBITORS Activx Biosciences, Inc. (US) 2009-06-10 EP disclosed
US-20080161290-A1 Serine hydrolase inhibitors KYORIN PHARMACEUTICAL CO., LTD. (JP) 2008-07-03 US disclosed
US-20080161290-A1 Serine hydrolase inhibitors KYORIN PHARMACEUTICAL CO., LTD. (JP) 2008-07-03 US disclosed
US-20080161290-A1 Serine hydrolase inhibitors KYORIN PHARMACEUTICAL CO., LTD. (JP) 2008-07-03 US disclosed
WO-2008036379-A2 SERINE HYDROLASE INHIBITORS ACTIVX BIOSCIENCES, INC. (US) 2008-03-27 WO disclosed
WO-2008036379-A2 SERINE HYDROLASE INHIBITORS ACTIVX BIOSCIENCES, INC. (US) 2008-03-27 WO disclosed
US-4745116-A INHIBITORS OF SERINE PROTEASE SYNTEX (U.S.A.) INC. (US) 1988-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080161290-A1 Serine hydrolase inhibitors SERPINB1, ELANE, EPX ALDH1A1 981/4885HPGD 72/4885HSD17B10 323/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.